Go Pro
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel Free NCYT Stock Alerts

Novacyt (NCYT) Competitors

Novacyt logo
GBX 45.20 -0.30 (-0.66%)
As of 04:26 AM Eastern
Compare

NCYT vs. SPEC, EKF, CREO, IUG, and BVC

Should you buy Novacyt stock or one of its competitors? Novacyt's main competitors and comparable companies include INSPECS Group (SPEC), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Novacyt compare to INSPECS Group?

Novacyt (LON:NCYT) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

INSPECS Group has a consensus target price of GBX 60, indicating a potential downside of 34.78%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts plainly believe INSPECS Group is more favorable than Novacyt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novacyt
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Novacyt has a beta of 1.112, suggesting that its share price is 11% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market.

INSPECS Group has a net margin of -2.67% compared to Novacyt's net margin of -103.08%. INSPECS Group's return on equity of -6.07% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-103.08% -96.44% -27.98%
INSPECS Group -2.67%-6.07%0.45%

INSPECS Group has higher revenue and earnings than Novacyt. INSPECS Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.64-£36.80M-£32.00N/A
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 0.4% of Novacyt shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Novacyt's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Novacyt Neutral
INSPECS Group Neutral

Summary

INSPECS Group beats Novacyt on 11 of the 14 factors compared between the two stocks.

How does Novacyt compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, EKF Diagnostics had 2 more articles in the media than Novacyt. MarketBeat recorded 2 mentions for EKF Diagnostics and 0 mentions for Novacyt. EKF Diagnostics' average media sentiment score of 0.34 beat Novacyt's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
EKF Diagnostics Neutral
Novacyt Neutral

EKF Diagnostics presently has a consensus target price of GBX 35, suggesting a potential upside of 37.80%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe EKF Diagnostics is more favorable than Novacyt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Novacyt
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.12£4.68M£0.4754.04
Novacyt£20.03M1.64-£36.80M-£32.00N/A

EKF Diagnostics has a net margin of 4.12% compared to Novacyt's net margin of -103.08%. EKF Diagnostics' return on equity of 3.01% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Novacyt -103.08%-96.44%-27.98%

EKF Diagnostics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, indicating that its stock price is 11% more volatile than the broader market.

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

EKF Diagnostics beats Novacyt on 15 of the 16 factors compared between the two stocks.

How does Novacyt compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -103.08%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -103.08%-96.44%-27.98%

Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, suggesting that its stock price is 11% more volatile than the broader market.

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.42-£25.04M£1.0012.88
Novacyt£20.03M1.64-£36.80M-£32.00N/A

In the previous week, Creo Medical Group had 1 more articles in the media than Novacyt. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Novacyt. Creo Medical Group's average media sentiment score of 0.75 beat Novacyt's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
Novacyt Neutral

Summary

Creo Medical Group beats Novacyt on 12 of the 13 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -103.08%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Novacyt -103.08%-96.44%-27.98%

Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, indicating that its stock price is 11% more volatile than the broader market.

In the previous week, Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Novacyt Neutral

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by company insiders. Comparatively, 0.4% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Intelligent Ultrasound Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Novacyt£20.03M1.64-£36.80M-£32.00N/A

Summary

Intelligent Ultrasound Group beats Novacyt on 7 of the 10 factors compared between the two stocks.

How does Novacyt compare to BATM Advanced Communications?

Novacyt (LON:NCYT) and BATM Advanced Communications (LON:BVC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

BATM Advanced Communications has higher revenue and earnings than Novacyt. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.64-£36.80M-£32.00N/A
BATM Advanced Communications£123.20M0.33-£278.26K-£4.20N/A

In the previous week, BATM Advanced Communications had 1 more articles in the media than Novacyt. MarketBeat recorded 1 mentions for BATM Advanced Communications and 0 mentions for Novacyt. BATM Advanced Communications' average media sentiment score of 0.66 beat Novacyt's score of 0.00 indicating that BATM Advanced Communications is being referred to more favorably in the news media.

Company Overall Sentiment
Novacyt Neutral
BATM Advanced Communications Positive

Novacyt has a beta of 1.112, indicating that its stock price is 11% more volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.754, indicating that its stock price is 25% less volatile than the broader market.

BATM Advanced Communications has a net margin of -14.90% compared to Novacyt's net margin of -103.08%. BATM Advanced Communications' return on equity of -22.13% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-103.08% -96.44% -27.98%
BATM Advanced Communications -14.90%-22.13%0.58%

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 14.3% of BATM Advanced Communications shares are owned by institutional investors. 0.4% of Novacyt shares are owned by company insiders. Comparatively, 31.0% of BATM Advanced Communications shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BATM Advanced Communications beats Novacyt on 10 of the 13 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

Export
MetricNovacytHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£32.77M£5.88B£7.32B£2.90B
Dividend YieldN/A1.75%2.54%6.17%
P/E Ratio-1.4126.54272.91367.67
Price / Sales1.6470.76639.2083,454.87
Price / Cash0.5833.7129.0327.89
Price / Book0.456.2211.387.31
Net Income-£36.80M£149.90M£3.47B£5.89B
7 Day Performance-1.74%1.12%2.16%0.56%
1 Month Performance18.95%9.16%7.59%3.17%
1 Year Performance12.72%8.03%25.16%22.34%

Novacyt Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 45.20
-0.7%		N/A+13.5%£32.77M£20.03MN/A120
SPEC
INSPECS Group
0.5977 of 5 stars		GBX 100
+3.1%		GBX 60
-40.0%		+111.3%£109.18M£191.70MN/A1,673
EKF
EKF Diagnostics
2.6733 of 5 stars		GBX 24.29
-1.2%		GBX 35
+44.1%		-7.3%£104.45M£51.56M51.69356
CREO
Creo Medical Group
N/AGBX 12.94
+1.5%		GBX 40
+209.1%		-4.9%£62.86M£6M12.94279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Bank of America grew this stake 139%
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The Musk-linked sector everyone's sleeping on
Micron, a key Musk supplier, surged 1,121% in under two years after Jeff Brown flagged it early. Now Brown ...
Brownstone Research | Sponsoredtc pixel